Quadrant Capital Group LLC Avenue Therapeutics, Inc. Transaction History

Quadrant Capital Group LLC

  • $1.42 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 12, 2021
SELL
$4.7 - $7.17 $521 - $795
-111 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$2.95 - $11.04 $327 - $1,225
111 New
111 $1,000

About AVENUE THERAPEUTICS, INC.

ATXI Quotes by TradingView
  • Ticker ATXI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,127,720
  • Market Cap $8.13M
  • Description
  • Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...
More about ATXI
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email